Immune Checkpoint Agonists for Inflammatory Skin Diseases

Affiliations

¹ Department of Dermatology, Yale School of Medicine, New Haven, Connecticut, USA. Electronic address: matthew.vesely@yale.edu.
² AnaptysBio, San Diego, California, USA; Department of Dermatology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, USA.
³ Lilly Biotechnology Center, San Diego, California, USA.
⁴ Department of Quantitative Biomedicine, University of Zurich, Zurich, Switzerland; Center for Human Immunology, University of Zurich, Zurich, Switzerland.
⁵ Montai Therapeutics, Cambridge, Massachusetts, USA; Deptartment of Dermatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA.

Matthew D Vesely et al. J Invest Dermatol. 2025 Jun.

. 2025 Jun;145(6):1268-1271.

doi: 10.1016/j.jid.2025.01.008. Epub 2025 Feb 8.

¹ Department of Dermatology, Yale School of Medicine, New Haven, Connecticut, USA. Electronic address: matthew.vesely@yale.edu.
² AnaptysBio, San Diego, California, USA; Department of Dermatology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, USA.
³ Lilly Biotechnology Center, San Diego, California, USA.
⁴ Department of Quantitative Biomedicine, University of Zurich, Zurich, Switzerland; Center for Human Immunology, University of Zurich, Zurich, Switzerland.
⁵ Montai Therapeutics, Cambridge, Massachusetts, USA; Deptartment of Dermatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA.